Cure8 research brief
A humanized DSS colitis model that recreates human T cell and myeloid responses could make preclinical testing of human-specific biologics (like anti-TNF antibodies) more relevant to people with IBD.
Researchers developing IBD therapeutics, translational immunologists, and clinicians interested in preclinical models for biologic drugs.
This abstract reports a new humanized mouse model (huHSC-NCG-M/hIL15) combined with DSS to induce colitis that supports reconstituted human T and myeloid cells and was used to test the anti-TNF biologic adalimumab.
The model showed weight loss, shortened colon length, epithelial damage after DSS, and partial rescue with adalimumab treatment, including reduced human TNF mRNA.
This classification is based on the journal abstract (structured content depth: abstract). The abstract reports use of adalimumab and human immune reconstitution but does not include full experimental details, peer-reviewed full-text data, or clinical outcomes in patients. Treat findings as preliminary preclinical model data.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study is comparing common biologics given after Crohn's surgery to prevent endoscopic recurrence—a key issue for people who have had bowel resection. Knowing which drugs perform better in real‑world practice could...
This trial is testing whether adding vedolizumab after autologous stem cell transplant can improve remission rates for people with severe Crohn's disease that has failed multiple therapies.
The article summarizes recent drug approvals and Phase 3 trial results that could affect which biologic treatments are available and how the Crohn's disease treatment market may change. It also gives epidemiology and...
